Most conventional strategies are designed to combat the gain-of-function associated with oncogenes (e.g., ERBB2 [41]), and all but ignore tumor suppressor genes due to the inherent complexities in restoring a loss-of-function(s) mutation within a tumor cell. The gene discussed is ERBB2; the disease is neoplasm.